Entering and Exiting the Medicare Part D Coverage Gap: Role of Comorbidities and Demographics
Some Medicare Part D enrollees whose drug expenditures exceed a threshold enter a coverage gap with full cost-sharing, increasing their risk for reduced adherence and adverse outcomes.
To examine comorbidities and demographic characteristics associated with gap entry and exit.
We linked 2005–2006 pharmacy, outpatient, and inpatient claims to enrollment and Census data. We used logistic regression to estimate associations of 2006 gap entry and exit with 2005 medical comorbidities, demographics, and Census block characteristics. We expressed all results as predicted percentages.
287,713 patients without gap coverage, continuously enrolled in a Medicare Advantage Part D (MAPD) plan serving eight states. Patients who received a low-income subsidy, could not be geocoded, or had no 2006 drug fills were excluded.
Of enrollees, 15.9% entered the gap, 2.6% within the first 180 days; among gap enterers, only 6.7% exited again. Gap entry was significantly associated with female gender and all comorbidities, particularly dementia (39.5% gap entry rate) and diabetes (28.0%). Among dementia patients entering the gap, anti-dementia drugs (donepezil, memantine, rivastigmine, and galantamine) and atypical antipsychotic medications (risperidone, quetiapine, and olanzapine) together accounted for 40% of pre-gap expenditures. Among diabetic patients, rosiglitazone accounted for 7.2% of pre-gap expenditures. Having dementia was associated with twice the risk of gap exit.
Certain chronically ill MAPD enrollees are at high risk of gap entry and exposure to unsubsidized medication costs. Clinically vulnerable populations should be counseled on how to best manage costs through drug substitution or discontinuation of specific, non-essential medications.
- Federal Register. Medicare Program Part D Final Rule, Medicare drug benefit effective CY 2006 (Title 1). Fed Regist [Rules and Regulations], Jan 28, 2005. 70:4193–4585. Available at: http://edocket.access.gpo.gov/2005/pdf/05-1321.pdf. Accessed January 15, 2010.
- Frakt, AB, Pizer, SD (2006) A first look at the new Medicare Prescription Drug Plans. Health Aff (Millwood) 25: pp. w252-61 CrossRef
- Hoadley J, Hargrave E, Merrell K, Cubanski J, Neuman T. Benefit design and formularies of Medicare Drug Plans: a comparison of 2006 and 2007 offerings (Menlo Park, Calif.: Henry J. Kaiser Family Foundation, Nov. 2006). Available at: http://www.kff.org/Medicare/upload/7589.pdf. Accessed: January 15, 2010.
- Summer L, Nemore P, Finberg J. Improving the Medicare Part D Program for the most vulnerable beneficiaries. 2007 May. Available at: http://www.commonwealthfund.org/publications/publications_show.htm?doc_id=484282. Accessed January 15, 2010.
- Pauly, MV (2004) Medicare drug coverage and moral hazard. Health Aff (Millwood) 23: pp. 113-22 CrossRef
- The Henry J. Kaiser Family Foundation. Medicare Part D 2008 data spotlight: premiums, November 2007. Available at: http://www.kff.org/Medicare/7706.cfm. Accessed January 15, 2010.
- IMS. IMS Special Report, Medicare Part D: The first year. Plymouth Meeting, PA. IMS Health, Inc; 2008.
- Stuart B, Simoni-Wastila L, Chauncey D. Assessing the impact of coverage gaps in the Medicare Part D drug benefit. Health Aff (Millwood). 2005;Suppl Web Exclusives:W5-167-W5-179.
- Tjia, J, Schwartz, JS (2006) Will the Medicare prescription drug benefit eliminate cost barriers for older adults with diabetes mellitus?. J Am Geriatr Soc 54: pp. 606-12 CrossRef
- Daniel, GW, Malone, DC (2007) Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. J Manag Care Pharm 13: pp. 142-54
- St Peter, WL (2008) Potential impact of Medicare Part D in the end-stage renal disease population. Adv Chronic Kidney Dis 15: pp. 140-6 CrossRef
- Evans-Molina, C, Regan, S, Henault, LE, Hylek, EM, Schwartz, GR (2007) The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. J Am Geriatr Soc 55: pp. 1038-43 CrossRef
- HCUP. Healthcare Cost and Utilization Project. Clinical Classifications Software (CCS) for ICD-9-CM. Agency for Healthcare Research and Quality 2008. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp#download. Accessed January 15, 2010.
- King, G, Tomz, M, Wittenberg, J (2000) Making the most of statistical analyses: improving interpretation and presentation. Am J Polit Sci 44: pp. 341-55 CrossRef
- U.S Census Bureau, Population Division. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007. May 2008. Available at: http://www.census.gov/popest/datasets.html. Accessed January 15, 2010.
- Federal Interagency Forum on Aging-Related Statistics. Older americans update 2006: key indicators of well-being. U.S.Government Printing Office, Washington, DC, May 2006.
- Goldman, DP, Joyce, GF, Zheng, Y (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298: pp. 61-9 CrossRef
- Boyd, CM, Darer, J, Boult, C, Fried, LP, Boult, L, Wu, AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294: pp. 716-24 CrossRef
- Fung V, Mangione CM, Huang J, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage Prescription Drug Plan beneficiaries with diabetes. Health Services Research; Under revise and resubmit, 2009.
- Cerfolio, RJ, Bryant, AS, Scott, E (2006) Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 130: pp. 1796-802 CrossRef
- West, JC, Wilk, JE, Muszynski, IL (2007) Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. Am J Psychiatry 164: pp. 789-96 CrossRef
- Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006;10(1):iii-iv, ix-xi, 1–160.
- Raina, P, Santaguida, P, Ismaila, A (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: pp. 379-97
- U.S. Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, April 11, 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm. Accessed January 31, 2010.
- Fillit, H, Geldmacher, DS, Welter, RT, Maslow, K, Fraser, M (2002) Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 50: pp. 1871-8 CrossRef
- Robinson, JC (2001) Physician organization in California: crisis and opportunity. Health Aff (Millwood) 20: pp. 81-96 CrossRef
- Schneider, EC, Zaslavsky, AM, Epstein, AM (2005) Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries. Am J Med 118: pp. 1392-400 CrossRef
- Hsu, J, Fung, V, Price, M (2008) Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA 299: pp. 1929-36 CrossRef
- Patel, RA, Lipton, HL, Cutler, TW, Smith, AR (2009) Cost minimization of Medicare part D prescription drug plan expenditures. Am J Manag Care 15: pp. 545-53
- Cox, ER, Jernigan, C, Coons, SJ, Draugalis, JL (2001) Medicare beneficiaries' management of capped prescription benefits. Med Care 39: pp. 296-301 CrossRef
- Tseng, CW, Brook, RH, Keeler, E, Mangione, CM (2003) Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA 290: pp. 222-7 CrossRef
- Tseng, CW, Brook, RH, Keeler, E, Steers, WN, Mangione, CM (2004) Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 292: pp. 952-60 CrossRef
- Hsu, J, Price, M, Huang, J (2006) Unintended consequences of caps on Medicare drug benefits. N Engl J Med 354: pp. 2349-59 CrossRef
- Shrank, WH, Fox, SA, Kirk, A (2006) The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med 21: pp. 334-9 CrossRef
- Wilson, IB, Schoen, C, Neuman, P (2007) Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors. J Gen Intern Med 22: pp. 6-12 CrossRef
- Piette, JD, Heisler, M, Wagner, TH (2004) Cost-related medication underuse: do patients with chronic illnesses tell their doctors?. Arch Intern Med 164: pp. 1749-55 CrossRef
- Berkowitz, SA, Gerstenblith, G, Anderson, GF (2007) Medicare prescription drug coverage gap: navigating the “doughnut hole” with patients. JAMA 297: pp. 868-70 CrossRef
- Lu, CY, Ross-Degnan, D, Soumerai, SB (2008) Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001–2007. BMC Health Serv Res 8: pp. 75 CrossRef
- Lexchin, J (2002) Effects of restrictive formularies in the ambulatory care setting. Am J Manag Care 8: pp. 69-76
- Burt, CW, Sisk, JE (2005) Which physicians and practices are using electronic medical records?. Health Aff (Millwood) 24: pp. 1334-43 CrossRef
- Entering and Exiting the Medicare Part D Coverage Gap: Role of Comorbidities and Demographics
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of General Internal Medicine
Volume 25, Issue 6 , pp 568-574
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- health insurance
- health care costs
- health services research
- health economics
- Industry Sectors
- Author Affiliations
- 1. Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, 911 Broxton Plaza, Los Angeles, CA, 90024, USA
- 2. Department of Health Services, UCLA School of Public Health, Los Angeles, CA, USA
- 3. Division of Research, Kaiser Permanente Medical Care Program, Northern California, Oakland, CA, USA